{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"PIWORLD Investor Podcasts","title":"Open Orphan (ORPH) at ShareSoc September 2019","html":"","width":"100%","height":180,"duration":2213,"description":"This video can be seen at: https://www.piworld.co.uk/2019/09/16/open-orphan-orph-at-sharesoc-september-2019/\n \nPresentation by Cathal Friel, Co-Founder\nORPH came out of a reverse takeover of Venn Life Sciences earlier this year. Cathal Friel outlines what they’re up to, and their vision.\nIntroduction – 00:18A pharma services company – 02:02The founders – 03:14The orphan drug sector – 06:48Combining high-margin pharma with digital & data offerings – 10:35Founders investment – 12:15Transforming Venn Life Sciences – 13:04Targetting to add Eu30m in high margin revenues by 2022 – 15:45Virtual Rep & Access platform – 18:45Open Orphan’s Geonomic Health Data Platform – 23:03Summary – 28:15Q&A – 30:45\nOpen Orphan plc, formerly Venn Life Sciences Holdings plc, is engaged in the pharma services business. The Company is also engaged in building an orphan drug consulting services platform that helps pharma companies commercialize their products in Europe. The Company consists of four elements: a European clinical research organization and consultancy; an orphan drug services business; a Virtual Rep and Data Access Platform consisting of physicians, and a Health Data Platform. The Company provides fragmented orphan drug services. The Company acquires and consolidates series of orphan drug services companies. It also provides digital data platforms to support companies in research & development and commercialization.","thumbnail_url":"https://img.transistorcdn.com/oB5fNE4aIAia_YyTCKvE1PzrZQaD1Fjo_P7m7T9Aw_Y/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9kOTJi/ODBiMzBmOGFhZWJi/MWEzYThkMzAyNmZm/MTdjZi5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}